Nvidia and Eli Lilly are teaming up on a $1 billion AI-powered lab to accelerate drug discovery, combining robotics, molecular modeling and automated research workflows.

EqoFlow has been accepted into the NVIDIA Inception program, NVIDIA’s global startup accelerator for AI innovators. The

Still, some investors have expressed concern about whether Nvidia may hold onto this top position. Well, here's some good news: Customers Alphabet ( GOOG 0.06%) ( GOOGL 0.08%) and Amazon ( AMZN 2.47%) just said something that may eliminate Nvidia's biggest risk.

Tesla focuses on vertically integrated products to preserve its valuation, while Nvidia strives to dominate the

NVIDIA’s new AI releases debut at CES 2026, including thirteen models and a supercomputer 5x faster than Blackwell, helping teams cut costs.

One big selling point of Rubin is dramatically lower AI inference costs. Compared to Nvidia's last-gen Blackwell platform, inference workloads on Rubin can be run at a 90% lower cost per token. Tokens are units of data processed by AI models, and it's how customers of those models are generally charged for use.

NVIDIA and Lilly bring together a world-leading, multidisciplinary team of scientists, AI researchers and engineers to address the

Nvidia unveiled the Vera Rubin AI computing platform at CES 2026, claiming up to 10x lower inference token costs and faster training for MoE models.

As Gen Z struggles to start their careers, Nvidia’s CEO Jensen Huang predicts “more hiring” is on the way—but only for workers who embrace AI.